Quantcast

Latest Naloxone Stories

2014-08-07 16:29:42

BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 RALEIGH, N.C., Aug. 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an...

2014-07-30 23:15:52

Mental Health Center at the Cedars-Sinai Medical Towers becomes the first medical practice in Los Angeles to distribute free prescription Naloxone to local treatment centers and sober living facilities. Beverly Hills, CA (PRWEB) July 30, 2014 On January 1, 2014, the Overdose Treatment Act (AB 635) became law in California. The law allows lay people to possess and administer prescription naloxone to someone in urgent need who is experiencing life-threatening respiratory depression from an...

2014-07-30 08:33:40

LONDON, July 30, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has received a funding commitment from a prominent international research and development foundation. The foundation has a focus on promoting innovative research-based initiatives, including those addressing health issues. Lightlake has been developing a nasal...

2014-07-23 08:31:41

LONDON, July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA"), part...

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-11 23:04:58

Harbor Village Florida comments how citizens of New Jersey are receiving training on how to administer opiate-overdose reversal drug Narcan. Ocean County, NJ (PRWEB) July 11, 2014 As reported by the Star Ledger in the article Officials To Give Out 100 Free Narcan Kits in Ocean County (7/3), 100 residents of Ocean County in New Jersey recently received free training on how to administer the drug Narcan, an opiate-overdose reversal drug as well as a free kit during this previous Fourth of...

2014-07-10 08:27:14

First and only FDA approved naloxone product specifically indicated for emergency therapy in settings where opioids may be present. RICHMOND, Va., July 10, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is not a...

2014-07-09 08:28:33

LONDON, July 9, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production...

2014-06-11 12:26:03

President and CEO Mark A. Sirgo Describes BUNAVAIL(TM) Delivery, Competitive Advantages, Market Size and Patient Need RALEIGH, N.C., June 11, 2014 /PRNewswire/ -- Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) was interviewed on Bloomberg TV, TheStreet.com and Business News Network on June 11 regarding BUNAVAIL, BDSI's product for the maintenance treatment of opioid dependence that recently received approval from...

2014-06-10 08:29:27

RALEIGH, N.C., June 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two important upcoming healthcare conferences: 34(th) Annual William Blair Growth Stock ConferenceWednesday, June 11, 20143:20 PM Central Time (4:20 PM Eastern Time)Four Seasons Hotel, Chicago, IL Wells Fargo 2014 Healthcare ConferenceTuesday, June 17, 20144:40 PM Eastern...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.